BECN1 and neuroblastoma: To confirm the effect of BECN1 in patients with NB, we performed a survival analysis of 1076 patients with NB enrolled in the TARGET public database and found that the 10‐year EFS and OS rates of patients with BECN1 mutations were poorer than those of patients without BECN1 mutations.